PRESS-RELEASE ·Filed Apr 24, 2026
Press release: earnings
Actionable Insight • Neutral
Monitor the April 30 earnings call for updates on cash runway, trial progress, and revenue trends. Given prior miss and lack of commercial revenue visibility, short interest may rise if guidance remains soft.
Final — all horizons settled through T+60d
SNDX ▲ +5.84% at T+60d
NEUTRAL call ✓ call won +5.84% · α vs SPY +0.76% · entry $21.39 → $22.64
T+1d
-1.82%
call -1.82% · α -1.99%
$21.00
settled 5mo ago
T+5d
+0.19%
call +0.19% · α -0.72%
$21.43
settled 5mo ago
T+20d
-7.57%
call -7.57% · α -11.60%
$19.77
settled 4mo ago
T+60d
+5.84%
call +5.84% · α +0.76%
$22.64
settled 2mo ago
Price Chart
Loading chart...
Executive Summary
Syndax Pharmaceuticals announced it will report Q1 2026 financial results and provide a business update on April 30, 2026. No financial results were released in this press release.
Key Facts
- Syndax Pharmaceuticals (SNDX) will report Q1 2026 financial results on April 30, 2026.
- This press release is an earnings announcement, not a results release — no financial data was disclosed.
- Prior quarter (Q4 2025) reported EPS of $-0.78, missing consensus of $-0.60 by 31%.
Financial Impact
No financials reported — upcoming results may impact sentiment
epsrevenue
Risk Factors
- History of EPS misses — Q4 2025 missed by 31%
- No near-term revenue catalysts disclosed; reliance on pipeline development
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Investment Themes
Biotech & Drug Discovery
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3280693 |
9 reports for SNDX
Track record builds as more directional reports settle.
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 14, 2026 11w ago | 8-K | $24.13 $20.29 | ▼ −15.91% | ▼ −18.41% | $17.60 (−27.06%) |
Jul 1, 2026 13w ago | Press Release | $21.82 $19.48 | ▼ −10.72% | ▼ −10.31% | $17.60 (−19.34%) |
Jun 11, 2026 16w ago | Press Release | $17.91 $24.84 | ▲ +38.69% | ▲ +36.80% | $17.60 (−1.73%) |
Jun 10, 2026 16w ago | 8-K | $17.91 $24.84 | ▲ +38.69% | ▲ +36.80% | $17.60 (−1.73%) |
Jun 4, 2026 17w ago | Press Release | $17.34 $22.08 | ▲ +27.34% | ▲ +25.47% | $17.60 (+1.50%) |
Jun 4, 2026 17w ago | DEFA14A | $18.02 $21.82 | ▲ +21.09% | ▲ +22.46% | $17.60 (−2.33%) |
Jun 4, 2026 17w ago | 8-K | $18.02 $21.82 | ▲ +21.09% | ▲ +22.46% | $17.60 (−2.33%) |
Apr 30, 2026 22w ago | DEFA14A | $19.11 $18.85 | ▼ −1.36% | ▼ −6.64% | $17.60 (−7.90%) |
Apr 24, 2026 23w ago | Press Release | $21.39 $19.77 | ▼ −7.57% | ▼ −11.60% | $17.60 (−17.72%) |
Showing 9 of 9
US Market Status
Market Closed — Opens Mon (38h 37m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access